GSK announces £275M construction plans

Manufacturing facility belonging to GlaxoSmithKilne is to be expanded as part of £275M investment into three sites.

GlaxoSmithKline is investing £275M into three of its manufacturing sites in the UK.

On the Angus site, a brand new state-of-the-art facility for the manufacture of respiratory active ingredients will be constructed, costing £110M.

Barnard Castle in County Durham will receive £92M to fund the construction of an aseptic sterile facility, while Ware in Hertfordshire will receive £74M for additional manufacturing capacity at the site.

The investment into the three sites not only create jobs in the construction industry , but will also support current employment at the sites, and create additional opportunities.

Chief Executive, Andrew Witty said the UK’s “competitive corporate tax system” and skilled workforce had influenced the decision to invest post-Brexit.

“Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products.

“It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world.”

UK government junior minister at the Scotland Office, Andrew Dunlop, said: “It is great news that GlaxoSmithKline is boosting investment in Scotland, and a real testament to the hard work and skills of the workforce in Montrose.  Above all, it is a clear vote of confidence in the country’s economy, and shows that Scotland and the UK are very much open for business.”

GlaxoSmithKline employs around 16,000 people in the UK.

 

If you would like to read more articles like this then please click here

The post GSK announces £275M construction plans appeared first on UK Construction Online.